This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Investor Calendar: Obesity Drugs

BOSTON ( TheStreet) -- Investors craving more action from obesity drug stocks have another catalyst looming within the next 10 days and a full calendar through the end of the year.

Vivus (VVUS - Get Report) is expected to announce top-line results from a follow-up study of its weight-loss drug combination Qnexa before the end of September. This study will provide two-year safety and efficacy data on Qnexa and possibly address one of the major shortcomings that compelled a U.S. advisory panel to vote against Qnexa in July.

Short sellers and skeptics of the current crop of experimental obesity drugs have had held the upper hand so far. Vivus shares tanked after the Qnexa setback in July. Last Thursday another negative vote by a U.S. advisory panel reviewing Arena Pharmaceuticals' (ARNA - Get Report) weight-loss drug lorcaserin caused that stock's value to also fall precipitously.

That leaves Orexigen Therapeutics (OREX - Get Report) as the next potential winner -- or victim -- depending on your point of view. Orexigen will bring its obesity drug Contrave in front of a yet another U.S. advisory panel on Dec. 7.

Vivus shares are down about 50% to $6 since the July panel vote. Arena shares, at $1.88, have lost more than 70% of their value in the past week. Orexigen, with the last obesity drug standing, has seen the value of its stock rise about 30% to $6 in the past week.

Before the Contrave panel, the U.S. Food and Drug Administration will issue approval decisions for lorcaserin on Oct. 22 and Qnexa on Oct. 28. The two decisive and negative advisory panel votes make it more likely that FDA will decide not to approve either drug at this time since the agency usually goes along with the recommendations of its advisory panels.

Vivus hopes to counteract the perception that Qnexa may not be safe enough for approval with two-year data from a double blind, randomized extension study known as "Sequel."

Patients in the Sequel study continued receiving the same treatment (either Qnexa or placebo) that they were receiving in a previous one-year phase III study. The goal of the Sequel study, which enrolled about 650 patients, is to measure the weight-loss efficacy and safety of Qnexa compared to placebo in patients treated over two years.

The lack of two-year data to assess Qnexa's longer-term safety was a significant sticking point with members of the FDA advisory panel who reviewed the drug in July.

Particular attention will be paid to the side effect profile of the high dose of Qnexa from the Sequel study, since this dose was where most of the worrisome side effects of the drug occurred.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARNA $4.04 1.60%
OREX $4.00 1.30%
VVUS $1.50 -14.00%
AAPL $121.55 -0.67%
FB $94.02 -1.20%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs